Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume – What’s Next?

Takeda Pharmaceutical Co. (NYSE:TAK) shares saw an uptick in trading volume on Thursday . 2,221,099 shares traded hands during mid-day trading, a decline of 26% from the previous session’s volume of 3,017,695 shares.The stock last traded at $16.5850 and had previously closed at $16.45.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Wall Street Zen downgraded Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Finally, Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Up 1.2%

The firm has a market capitalization of $52.97 billion, a price-to-earnings ratio of 42.68 and a beta of -0.07. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average price is $16.11 and its 200 day moving average price is $16.97.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. As a group, research analysts forecast that Takeda Pharmaceutical Co. will post 1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TAK. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the period. UBS Group AG increased its holdings in Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after buying an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd raised its position in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after buying an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp lifted its stake in Takeda Pharmaceutical by 98.4% during the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after acquiring an additional 1,143,117 shares during the period. Finally, Voloridge Investment Management LLC lifted its stake in Takeda Pharmaceutical by 1,070.7% during the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after acquiring an additional 880,289 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.